What Specific NMPA Regulatory Hurdles Exist for Novel Peptide Therapies in China?
The NMPA presents hurdles for novel peptide therapies through stringent clinical trial requirements, complex classification, and manufacturing quality controls, all ensuring patient safety and efficacy.
HRTioJuly 23, 2025